Failure (biologic function)
PTC Therapeutics Sells Priority Review Voucher for $150M Following Phase 2 ALS Trial Failure
PTC Therapeutics, ALS, Phase 2 trial failure, priority review voucher, $150M sale
Outlook Therapeutics Stock Crashes Following Clinical Trial Failure for Wet AMD Therapy
Outlook Therapeutics, OTLK, stock price, clinical trial failure, wet AMD therapy, ONS-5010, FDA filing
Alector Cuts 17% of Workforce Following Failure of AbbVie-Partnered Alzheimer’s Drug in Phase 2 Trial
Alector, layoffs, AbbVie, Alzheimer’s disease, phase 2 trial failure, biotech industry
Cassava Sciences’ Alzheimer’s Drug Fails in Clinical Trial, Stock Plummets
Cassava Sciences, Alzheimer’s disease, clinical trial failure, ReThink-ALZ study, stock decline
Gilead Exceeds COVID-19 Drug Sales Projections, Faces $1.75 Billion Loss on Trodelvy Trial Failure
Gilead, COVID-19, Veklury, Trodelvy, drug sales, clinical trial failure
Novo Nordisk Terminates Development of Kidney Disease Drug Ocedurenone After Phase 3 Failure
Novo Nordisk, ocedurenone, kidney disease, hypertension, Phase 3 trial, CLARION-CKD, drug development failure
Spero Therapeutics Slashes 39% of Workforce Following Phase 2 Antibiotic Trial Failure
Spero Therapeutics, antibiotic trial failure, workforce reduction, biotech layoffs, cash runway extension
GSK’s Therapeutic Herpes Vaccine Fails to Meet Efficacy Objective in Phase I/II Trial
GSK, therapeutic herpes vaccine, herpes simplex virus, HSV, vaccine failure, clinical trial
LEO Pharma’s Acquisition of Timber Pharmaceuticals’ Assets Faces Setback Due to Late-Stage Study Failure
LEO Pharma, Timber Pharmaceuticals, TMB-001, congenital ichthyosis, late-stage study failure, asset acquisition
Ventyx Abandons TYK2 Inhibitor Development Following Phase II Failure in Crohn’s Disease
Ventyx Biosciences, TYK2 inhibitor, VTX958, Crohn’s disease, Phase II trial, drug development failure